Iovance’s registrational lung cancer trial on hold after patient death

The FDA placed a clinical hold on a registrational trial of Iovance Biotherapeutics’ tumor-infiltrating lymphocyte, or TIL, therapy LN-145 after a patient death in the study.

The hold puts a dent in the development of Iovance’s second-most advanced treatment candidate, and investors sent its shares Click here to view original post

Advertisement — Advertise with Biotech Networks